Clinical Information

Clinical Information

Range of Motion Results

More movement:
TURALIO significantly improved ROM for the affected joints compared with placebo, assessed at week 25 as mean percentage change from baseline, relative to a reference standard for the same joint1

  • The total population studied was 120 patients. Results were excluded for 1 patient with missing baseline and 31 patients with a missing ROM assessment at week 251
  • Joints represented in the analysis (TURALIO vs placebo, respectively) included the knee (n = 25; n = 28), ankle (n = 11; n = 7), and other (n = 9; n = 8)3
  • Assessments were performed by a third-party clinical assessor using a goniometer1
Secondary endpoint: Change in ROM from baseline in affected joint at week 251,a
envilen-clinical-study envilen-clinical-study

RECIST, Response Evaluation Criteria In Solid Tumors; ROM, range of motion.

aRelative to the reference standard for affected joint.

Interested in TURALIO?

Request to speak with a Daiichi Sankyo representative to get more information and resources about TURALIO.